AoXiang Pharmaceuticals: Lucotinib Phosphate receives approval notice for the listing of the chemical raw material drug

MetaMuskRat · 2026-04-01T23:43:04+00:00

People's Financial News, March 31 — Aoxiang Pharmaceutical Co., Ltd. ((603229)) announced on March 31 that it has received the "Approval Notice for the Marketing Application of the Raw Material Drug" for phospho-rituximab (Liposomal) issued by the National Medical Products Administration. Phospho-rituximab is indicated for the treatment of adult patients with splenomegaly and related symptoms secondary to intermediate- or high-risk primary myelofibrosis, secondary myelofibrosis caused by polycythemia vera, or secondary myelofibrosis due to essential thrombocythemia.

MetaMuskRat

2026-04-01 23:43:04

People’s Finance News, March 31—On March 31, Ao Xiang Pharmaceutical (603229) announced that the company received a “Chemical Drug Substance (API) Marketing Application Approval Notice” issued and approved by the National Medical Products Administration for its ruxolitinib phosphate raw material. Ruxolitinib phosphate is indicated for the treatment of adult patients with splenomegaly and related symptoms, including those with intermediate-risk or high-risk primary myelofibrosis, myelofibrosis in adult patients secondary to polycythemia vera, and myelofibrosis in adult patients secondary to essential thrombocythemia.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes